TGFB1 and neoplasm: Inhibition of CYP19A1 resulted in the downregulation of PD-L1, IL-6 and TGF-β expression in colon cancer cells, thereby enhancing the tumor-killing ability of CD8+ T cells (Liu et al., 2023).